As of Dec. 2, 10 oseltamivir products from five drugmakers were in short supply, according to the American Society of Health-System Pharmacists. The update is a minor improvement from a month ago when there were 12 products from six companies part of the dearth.
The back-ordered and allocated products include three from Amneal Pharmaceuticals, three from Camber Pharmaceuticals, two from Macleods Pharma, one from Zydus Lifesciences and one from Teva Pharmaceuticals.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
